JP Morgan Chase’s Bio-Path Holdings BPTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
– Sell
-217
Closed -$252 – 7911
2024
Q4
$252 Buy
+217
New +$202 ﹤0.01% 6897
2023
Q3
– Sell
-22
Closed -$306 – 7421
2023
Q2
$766 Sell
22
-1
-4% -$31 ﹤0.01% 6508
2023
Q1
$1K Buy
+23
New +$828 ﹤0.01% 6599
2020
Q1
– Hold
0
– – – 5830
2019
Q4
– Hold
0
– – – 5977
2019
Q3
– Hold
0
– – – 6053
2019
Q2
– Hold
0
– – – 6102
2019
Q1
– Hold
0
– – – 6135
2018
Q4
– Hold
0
– – – 6018
2018
Q3
– Hold
0
– – – 5909
2018
Q2
– Hold
0
– – – 5764
2018
Q1
– Hold
0
– – – 5711
2017
Q4
– Hold
0
– – – 5645
2017
Q3
– Hold
0
– – – 4950
2017
Q2
– Sell
-15
Closed -$31.5K – 4922
2017
Q1
$49K Sell
15
-15
-50% -$54.5K ﹤0.01% 4561
2016
Q4
$163K Buy
+30
New +$145K ﹤0.01% 4264
2015
Q3
– Sell
-4
Closed -$18K – 4156
2015
Q2
$18K Buy
+4
New +$21.9K ﹤0.01% 3979

Other funds holding BPTH

JP Morgan Chase's BPTH Position: Q1 2025 in Review

JP Morgan Chase sold out of Bio-Path Holdings (BPTH) in Q1 2025, closing a stake of 217 shares — an estimated $252 sold.

JP Morgan Chase first reported a position in BPTH in Q2 2015 and held it in 6 quarters. The position peaked at $163K in Q4 2016. 2 funds tracked by Wall St. Rank hold BPTH as of Q1 2025.

  • JP Morgan Chase reported no remaining Bio-Path Holdings position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 217 Bio-Path Holdings shares in Q1 2025, an estimated $252.
  • JP Morgan Chase first reported a position in Bio-Path Holdings in Q2 2015 and held it in 6 quarters.
  • JP Morgan Chase's Bio-Path Holdings position peaked at $163K in Q4 2016.
  • 2 funds tracked by Wall St. Rank held Bio-Path Holdings as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.